iPhone Screenshots
Description
A Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression (TPS ≥ 50%). This app is specifically intended for participants in the J3M-MC-JZQB study only.